1/3×/04

Docket No. MCP-242

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Harry S. Sowden

Serial No.: 09/966,939

Art Unit: 1722

Filed

: September 28, 2001

Examiner: Robert B. Davis

For

: SYSTEMS, METHODS AND APPARATUSES FOR MANUFACTURING

DOSAGE FORMS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner Por Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

December 4, 2003

David R. Crichton
(Name of applicant, assignes, or Registered Representative)

December 4, 2003

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SIXTH INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

☐ In accord	ance with §1.129(a), this Information
Disclosure Statemen	t is being filed in connection with $\square$ the
first or Second A	fter Final Submission, therefore:
☐ Stat	ement in Accordance with §1.97(e)
(att	ached); or
☐ Plea	se charge Deposit Account No. 10-
0750	/
in §	1.17(p).

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).
In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
○ Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
accached Form F10-1445 are chorough northways.
Copies of references listed on the attached Form PTO
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
•
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

There are no listed references which are not in the English language.
The relevance of those listed references which are not in the English language is as follows:
Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.
Attached are the following non-published pending patent applications which may be deemed relevant, which are

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/MCP-242/DRC. This form is submitted in triplicate.

listed on the attached Submission Under MPEP 609 D.

Respectfully submitted,

David R. Crichton

Reg. No. 37,300

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-6131 DATED: December 4, 2003